Saturday, 31 October 2026European Markets

CGG Stock Was 9.49% Up Today

Loading stream...

(vianews) - the market ended the session with cgg (cgg.pa) rising 9.49% to €0.61 on thursday, following the last session's upward trend. cac 40 jumped 0.59% to €7,575.85, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

cgg's last close was €0.56, 42.27% under its 52-week high of €0.96.

about cgg

cgg provides data, products, services, and solutions in earth science, data science, sensing, and monitoring in north america, the central and south americas, europe, africa, the middle east, and the asia pacific. it operates through two segments, data, digital & energy transition (dde); and sensing & monitoring (smo). the dde segments engages in the developing and licensing earth data seismic surveys; processing and imaging seismic data; sale of seismic data processing software under the geovation brand; provision of geoscience and petroleum engineering consulting services; and collecting, developing, and licensing geological data. the smo segment is involved in the design, engineering, and manufacturing of seismic equipment for the land and marine seismic data acquisition, including seismic recording equipment, software and seismic sources for land vibrators or marine sources, and sensing and monitoring equipment and solutions under the sercel, metrolog, grc, deregt, and geocomp brand names. this segment also provides customer support services, such as training. the company provides solutions for natural resources, environmental, infrastructure, energy transition, and digital applications. the company was formerly known as compagnie générale de géophysique — veritas sa and changed its name to cgg in 2013. cgg was incorporated in 1931 and is headquartered in massy, france.

earnings per share

as for profitability, cgg has a trailing twelve months eps of €0.1.

pe ratio

cgg has a trailing twelve months price to earnings ratio of 6.09. meaning, the purchaser of the share is investing €6.09 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.41%.

revenue growth

year-on-year quarterly revenue growth grew by 15%, now sitting on 1.08b for the twelve trailing months.

volatility

cgg's last week, last month's, and last quarter's current intraday variation average was a negative 0.20%, a negative 0.75%, and a positive 2.13%.

cgg's highest amplitude of average volatility was 3.19% (last week), 1.84% (last month), and 2.13% (last quarter).

volume

today's last reported volume for cgg is 15108700 which is 106.61% above its average volume of 7312520.

more news about cgg (cgg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com